#1 Clinical Trials Search in Europe

Mps-200

This article summarizes several clinical trials investigating the use of OSE2101 (TEDOPI), a cancer vaccine containing multiple synthetic peptides, for treating various types of cancer including non-small cell lung cancer, ovarian cancer, and pancreatic cancer. The trials aim to evaluate the safety and efficacy of OSE2101 alone or in combination with other therapies as maintenance treatment or in advanced disease settings.

Table of Contents

What is MPS-200?

MPS-200 is an experimental cancer vaccine that is currently being studied in clinical trials[1]. It is one of the active substances in a medication called TEDOPI, which is being developed by OSE Immunotherapeutics[2]. TEDOPI is described as a “preservative-free, sterile product containing 10 synthetically manufactured peptides”[3]. In simpler terms, it’s a mixture of small proteins designed to stimulate the immune system to fight cancer.

How Does MPS-200 Work?

MPS-200 is part of a class of treatments called cancer vaccines. Unlike vaccines that prevent diseases, cancer vaccines are designed to treat existing cancers. They work by training the immune system to recognize and attack cancer cells[1].

Specifically, MPS-200 and the other peptides in TEDOPI are designed to target cells that have a specific marker called HLA-A2. This marker is found on many cancer cells. By targeting this marker, the vaccine aims to help the immune system identify and destroy cancer cells while leaving healthy cells alone[2].

What Conditions is MPS-200 Being Studied For?

Based on the clinical trials information, MPS-200 (as part of TEDOPI) is being studied for several types of cancer[1][2][3][4]:

  • Non-Small Cell Lung Cancer (NSCLC): This is a type of lung cancer that accounts for most lung cancer cases.
  • Ovarian Cancer: Specifically, platinum-sensitive recurrent ovarian cancer.
  • Pancreatic Cancer: Particularly locally advanced or metastatic pancreatic ductal adenocarcinoma.
  • Other Advanced Solid Tumors: Some trials are also looking at its effects on various other types of advanced cancers.

Current Clinical Trials

Several clinical trials are currently underway to study MPS-200 as part of TEDOPI[1][2][3][4]:

  • ARTEMIA Study: This is a phase 3 trial comparing TEDOPI to chemotherapy in patients with advanced Non-Small Cell Lung Cancer who have previously received immunotherapy.
  • TEDOVA Study: A phase 2 trial studying TEDOPI alone or in combination with another immunotherapy drug in patients with ovarian cancer.
  • TEDOPAM Study: This phase 2 trial is looking at TEDOPI in combination with chemotherapy for pancreatic cancer.
  • Another phase 1/2 study is examining TEDOPI in combination with other immunotherapy drugs for various advanced cancers.

Potential Benefits

While it’s important to note that MPS-200 is still experimental, the clinical trials are designed to assess several potential benefits[1][2][3][4]:

  • Improved Survival: Many of the trials are looking at whether TEDOPI can help patients live longer.
  • Tumor Shrinkage: Researchers are measuring if the treatment can cause tumors to shrink or disappear.
  • Delayed Disease Progression: Studies are examining if TEDOPI can slow down or stop cancer growth.
  • Quality of Life: Some trials are assessing if the treatment can improve patients’ overall well-being and symptoms.

Possible Side Effects

As with any medical treatment, MPS-200 may cause side effects. The full range of potential side effects is still being studied in clinical trials. However, common side effects of cancer vaccines can include[1][2]:

  • Injection site reactions (redness, swelling, pain)
  • Flu-like symptoms (fever, chills, fatigue)
  • Nausea
  • Muscle or joint pain

More serious side effects are possible, which is why the treatment is being carefully studied in clinical trials.

Who May Be Eligible for MPS-200 Trials?

Eligibility for MPS-200 trials varies depending on the specific study. However, some common criteria include[1][2][3][4]:

  • Having a specific type of cancer being studied (e.g., NSCLC, ovarian cancer, pancreatic cancer)
  • Having cancer that is advanced or has spread
  • Having received certain previous treatments
  • Having the HLA-A2 marker on their cells
  • Being in overall good health apart from their cancer

It’s important to note that each trial has its own specific eligibility criteria. Patients interested in participating should discuss options with their healthcare provider.

Conclusion

MPS-200, as part of the TEDOPI cancer vaccine, represents a promising area of cancer research. By harnessing the power of the immune system, it offers a potential new approach to treating several types of advanced cancer. While the results of ongoing clinical trials are eagerly awaited, it’s important to remember that MPS-200 is still experimental. Patients interested in this treatment should discuss current options and potential clinical trial participation with their healthcare team.

Trial Name Cancer Type Phase Treatment Primary Endpoint
ARTEMIA Metastatic NSCLC III OSE2101 vs. docetaxel Overall Survival
Unnamed Advanced solid tumors, lymphomas, NSCLC I/II OSE-279 (PD-1 inhibitor) +/- OSE2101 Safety, MTD, RP2D, ORR
TEDOVA Recurrent ovarian cancer II OSE2101 +/- pembrolizumab vs. best supportive care Progression-Free Survival
TEDOPAM Advanced pancreatic cancer II OSE2101 + FOLFIRI vs. FOLFIRI alone Overall Survival at 12 months

FAQ

  • What is OSE2101 (TEDOPI)? OSE2101, also known as TEDOPI, is a cancer vaccine containing multiple synthetic peptides designed to stimulate the immune system to target cancer cells. It is being investigated as a potential treatment for various types of cancer.
  • What types of cancer are being studied with OSE2101? The clinical trials are investigating OSE2101 for non-small cell lung cancer (NSCLC), ovarian cancer, and pancreatic cancer.
  • How is OSE2101 administered? OSE2101 is administered as an injection, typically subcutaneously (under the skin).
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety and efficacy of OSE2101, either alone or in combination with other therapies, as a maintenance treatment or for advanced stages of cancer. The trials are measuring outcomes such as overall survival, progression-free survival, and tumor response rates.
  • Who is eligible to participate in these trials? Eligibility varies by trial but generally includes adult patients with specific cancer types, adequate organ function, and certain genetic markers like HLA-A2 positivity. Patients must meet other criteria related to prior treatments and overall health status.

Ongoing Clinical Trials on Mps-200

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • OSE2101 (TEDOPI): A cancer vaccine containing multiple synthetic peptides designed to stimulate the immune system against cancer cells.
  • HLA-A2: A specific type of human leukocyte antigen (HLA) found on cells. Patients who are HLA-A2 positive may be eligible for certain treatments targeting this marker.
  • NSCLC: Non-small cell lung cancer, a type of lung cancer that is the focus of some OSE2101 trials.
  • Maintenance therapy: Treatment given to help keep cancer from coming back after it has responded to initial therapy.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Immune checkpoint inhibitor: A type of drug that blocks certain proteins made by immune system cells and some cancer cells, potentially allowing the immune system to attack cancer cells more effectively.
  • FOLFIRINOX: A combination chemotherapy regimen used to treat pancreatic cancer, consisting of folinic acid, fluorouracil, irinotecan, and oxaliplatin.
  • Sarcopenia: Age-related loss of muscle mass and function, which may affect how patients respond to cancer treatments.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/
  4. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/